Omnicell (NASDAQ:OMCL) Price Target Raised to $30.00 at Wells Fargo & Company

Omnicell (NASDAQ:OMCL) had its target price increased by Wells Fargo & Company from $26.00 to $30.00 in a research report sent to investors on Friday morning, Benzinga reports. They currently have an equal weight rating on the stock.

OMCL has been the subject of a number of other reports. StockNews.com lowered shares of Omnicell from a buy rating to a hold rating in a report on Tuesday, July 16th. Benchmark reiterated a buy rating and set a $38.00 target price on shares of Omnicell in a research report on Monday, July 15th. Finally, Barclays upgraded Omnicell from an underweight rating to an equal weight rating and raised their price target for the company from $26.00 to $39.00 in a research note on Friday. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, Omnicell presently has a consensus rating of Hold and an average price target of $38.00.

Omnicell Trading Up 2.0 %

Shares of NASDAQ OMCL opened at $40.00 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.13 and a current ratio of 2.45. The firm’s 50 day moving average price is $28.84 and its 200-day moving average price is $29.04. Omnicell has a 52-week low of $25.12 and a 52-week high of $66.65. The company has a market cap of $1.84 billion, a PE ratio of -86.96, a P/E/G ratio of 108.76 and a beta of 0.80.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, August 1st. The company reported $0.51 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.37. The company had revenue of $276.80 million during the quarter, compared to analyst estimates of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The firm’s quarterly revenue was down 7.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.29 EPS. On average, equities research analysts expect that Omnicell will post 0.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Omnicell

Several institutional investors and hedge funds have recently added to or reduced their stakes in OMCL. Raymond James & Associates grew its stake in Omnicell by 3.6% in the fourth quarter. Raymond James & Associates now owns 94,907 shares of the company’s stock valued at $3,571,000 after purchasing an additional 3,254 shares during the last quarter. Trust Point Inc. purchased a new stake in shares of Omnicell during the fourth quarter worth about $342,000. Arkadios Wealth Advisors grew its stake in shares of Omnicell by 6.2% during the fourth quarter. Arkadios Wealth Advisors now owns 22,985 shares of the company’s stock worth $865,000 after acquiring an additional 1,341 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Omnicell by 3.2% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 638,646 shares of the company’s stock worth $24,032,000 after acquiring an additional 19,601 shares during the last quarter. Finally, Louisiana State Employees Retirement System purchased a new stake in shares of Omnicell during the fourth quarter worth about $854,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.